Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Retained Earnings (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Retained Earnings data on record, last reported at $3.2 billion in Q1 2024.

  • For Q1 2024, Retained Earnings rose 21.79% year-over-year to $3.2 billion; the TTM value through Mar 2024 reached $3.2 billion, up 21.79%, while the annual FY2025 figure was $3.7 billion, 15.38% up from the prior year.
  • Retained Earnings reached $3.2 billion in Q1 2024 per RDY's latest filing, up from $2.6 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $3.2 billion in Q1 2024 and bottomed at $14.0 million in Q1 2020.
  • Average Retained Earnings over 5 years is $2.1 billion, with a median of $2.3 billion recorded in 2022.
  • Peak YoY movement for Retained Earnings: tumbled 47.48% in 2020, then skyrocketed 15172.88% in 2021.
  • A 5-year view of Retained Earnings shows it stood at $14.0 million in 2020, then surged by 15172.88% to $2.1 billion in 2021, then rose by 9.2% to $2.3 billion in 2022, then rose by 12.23% to $2.6 billion in 2023, then rose by 21.79% to $3.2 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $3.2 billion in Q1 2024, $2.6 billion in Q1 2023, and $2.3 billion in Q1 2022.